Adherence to guidelines on nutrition support during intensive treatment of acute myeloid leukemia patients: A nationwide comparison

Lieshout, Rianne van; Tick, Lidwine W.; Laat, D. de; Custers, Stephanie; Dekker, Ingeborg M.; Douma, Madieke D; Kalter, D.; Kranenburg, Suzanne; Lee, D. van der; Rhoon-Bruijnzeel, Patricia; Schlösser, Ien; Somer, M. Filip De; Tilborg, Claudia J. van; Visser, W.K.; Schouten, Harry C.; Beijer, Sandra

doi:10.1016/j.clnesp.2020.09.176

Cited by 1 publication

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…95 Subsequently, the European Society for Clinical Nutrition and Metabolism established guidelines for malnutrition risk screening and recommendations for intervention, albeit these are poorly adhered to in AML clinical care management. 96 This may be due to the scarcity of information pertinent to AML. Parenteral feeding has been touted as preferential over enteral feeding due to common oncological challenges (i.e.…”

Section: Malnutrition and Metabolic Dysregulationmentioning

confidence: 99%

“…Unsurprisingly, patients who are malnourished prior to HCT are at increased risk of adverse treatment outcomes 95 . Subsequently, the European Society for Clinical Nutrition and Metabolism established guidelines for malnutrition risk screening and recommendations for intervention, albeit these are poorly adhered to in AML clinical care management 96 . This may be due to the scarcity of information pertinent to AML.…”

Section: An Opportunity To Waste: Exploring the Multifactorial Contri...mentioning

confidence: 99%

See 1 more Smart Citation

Cachectic muscle wasting in acute myeloid leukaemia: a sleeping giant with dire clinical consequences

Campelj

Timpani

Rybalka

2021

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

Acute myeloid leukaemia (AML) is a haematological malignancy with poor survival odds, particularly in the older (>65 years) population, in whom it is most prevalent. Treatment consists of induction and consolidation chemotherapy to remit the cancer followed by potentially curative haematopoietic cell transplantation. These intense treatments are debilitating and increase the risk of mortality. Patient stratification is used to mitigate this risk and considers a variety of factors, including body mass, to determine whether a patient is suitable for any or all treatment options. Skeletal muscle mass, the primary constituent of the body lean mass, may be a better predictor of patient suitability for, and outcomes of, AML treatment. Yet skeletal muscle is compromised by a variety of factors associated with AML and its clinical treatment consistent with cachexia, a life‐threatening body wasting syndrome. Cachectic muscle wasting is associated with both cancer and anticancer chemotherapy. Although not traditionally associated with haematological cancers, cachexia is observed in AML and can have dire consequences. In this review, we discuss the importance of addressing skeletal muscle mass and cachexia within the AML clinical landscape in view of improving survivability of this disease.

show abstract

Section: Malnutrition and Metabolic Dysregulationmentioning

confidence: 99%

Section: An Opportunity To Waste: Exploring the Multifactorial Contri...mentioning

confidence: 99%

Cachectic muscle wasting in acute myeloid leukaemia: a sleeping giant with dire clinical consequences

Campelj

Timpani

Rybalka

2021

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

show abstract

Adherence to guidelines on nutrition support during intensive treatment of acute myeloid leukemia patients: A nationwide comparison

Abstract: Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Cited by 1 publication

References 30 publications

Cachectic muscle wasting in acute myeloid leukaemia: a sleeping giant with dire clinical consequences

Cachectic muscle wasting in acute myeloid leukaemia: a sleeping giant with dire clinical consequences

Contact Info

Product

Resources

About